1 domain / 1 area / 1 specialization
Ally Bridge Group
Also known as: ABG
Data updated
Ally Bridge Group is a global healthcare investment management firm investing across private and public life-science markets. Its website emphasizes cross-market healthcare investing, with teams and offices spanning New York and Hong Kong.
Within psychedelic medicine, Ally Bridge is relevant through atai's 2025 private placement. This makes it a healthcare crossover investor in the sector, not a dedicated psychedelic investor.
Investor Context
Institutional InvestorsInvestment Context
This stakeholder is listed as an Institutional Investor within Institutional Investors. Its public geography context is global. Public stage signals include Growth / Late Stage, Public Markets, and Multi-Stage. Public focus areas include Drug Development, Digital Therapeutics & Platforms, and Manufacturing & Supply Chain.
Public Portfolio Examples
- atai Life SciencesPrivate placement financing - approximately $50 million - Jul 1, 2025
- AtaiBeckleyPortfolio stakeholder
Ally Bridge Group represents institutional healthcare capital with source-backed exposure to atai. Its role is best described through healthcare innovation and life-science investing rather than psychedelic specialization.
Investor Type
Institutional Investor
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Portfolio Stakeholders
Recorded Investments
Jul 1, 2025
Private placement financing - approximately $50 million
Shows institutional healthcare crossover capital in a flagship psychedelic platform.
atai Life Sciences Announces $50 Million Private Placement FinancingQuick Facts
- Founded
- 2013
- HQ
- New York, United States
- Website
- Visit